Supplementary Figure S1 A B MTT MTT LDH activity 1100 · A B MTT LDH activity C. Supplementary...
8
600 700 800 900 1000 1100 LDH activity (mU/ml) + + + + + E. coli (1:10) 0 0.1 0.3 1 3 Mg-ATP (mM) 0.0 0.2 0.4 0.6 0.8 1.0 1.2 OD 550nm + + + + + E. coli (1:10) 0 0.1 0.3 1 3 Mg-ATP (mM) Supplementary Figure S1 A B MTT LDH activity C
Transcript of Supplementary Figure S1 A B MTT MTT LDH activity 1100 · A B MTT LDH activity C. Supplementary...
600
700
800
900
1000
1100
LDH
act
ivity
(mU
/ml)
+ + + + + E. coli (1:10)0 0.1 0.3 1 3 Mg-ATP (mM)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
OD
550n
m
+ + + + + E. coli (1:10)0 0.1 0.3 1 3 Mg-ATP (mM)
MTT
Supplementary Figure S1
A BMTT LDH activity
C
Supplementary Figure S2
Supplementary Figure S3
A B
0
2
4
6
8
rela
tive
chem
otac
tic in
dex
- + + + + +
WT
0 0.1 0.3 1 3
100 ng/ml MCP-1
Mg-ATP (mM)
P2X4R-/-
- + + + + + 0 0.1 0.3 1 3
*** ***
0
3000
6000
9000
12000
15000
MFI
/ 105 c
ell
+ + + + + + + + + + E. coli0 0.1 0.3 1 3 0 0.1 0.3 1 3 Mg-ATP (mM)
WT P2X4R-/-
WT P2X4R-/- WT P2X4R-/-0
2000
4000
6000
8000
CK
(U/L
)
SHAM CLP
Supplementary Figure S4
A B C
D E F
G H I
WT P2X4R-/- WT P2X4R-/-0
250
500
750
1000
ALT
(U/L
)
SHAM CLP
WT P2X4R-/- WT P2X4R-/-0
300
600
900
1200
AST
(U/L
)
SHAM CLP
WT→WT P2X4R-/-→WT0
100
200
300
400
500
ALT
(U/L
)
WT→WT P2X4R-/-→WT0
200
400
600
AST
(U/L
)
WT→WT P2X4R-/-→WT0
2500
5000
7500
CK
(mg/
ml)
0
200
400
600
ALT
(U/L
)
veh 10 mg/kgivermectin
0
300
600
900
1200
1500
AST
(U/L
)
veh 10 mg/kgivermectin
0
5000
10000
15000
CK
(mg/
ml)
veh 10 mg/kgivermectin
LAVAGE
LysM-Cre P2X4Rfl/fl-LysM-Cre0
50
100
150
200
TNFα
(pg/
ml)
LAVAGE
LysM-Cre P2X4Rfl/fl-LysM-Cre0
200
400
600
800
1000
IL-1β
(pg/
ml)
*BLOOD
LysM-Cre P2X4Rfl/fl-LysM-Cre0
50
100
150
TNFα
(pg/
ml)
*BLOOD
LysM-Cre P2X4Rfl/fl-LysM-Cre0
100
200
300
400
500
600
700
IL-1β
(pg/
ml)
LAVAGE
WT→WT P2X4R-/-→WT0
200
400
600
800
1000
TNFα
(pg/
ml)
LAVAGE
WT→WT P2X4R-/-→WT0.0
0.5
1.0
1.5
IL-1β
(ng/
ml)
BLOOD
WT→WT P2X4R-/-→WT0
50
100
150
200
TNFα
(pg/
ml)
BLOOD
WT→WT P2X4R-/-→WT0.000
0.005
0.010
0.015
0.020
IL-1β
(ng/
ml)
Supplementary Figure S5
A C DB
E F G H
Supplementary Figure S6
0.0
0.2
0.4
0.6
0.8
1.0
1.2
P2X
4 m
RN
A (-
fold
cha
nge)
P2X4Rfl/fl-LysM-Cre
LysM-Cre
i.p. Mφ liver spleen kidney thymus heart brain
LAVAGE
0
5
10
15
20
MIP
-2 (n
g/m
l)
veh 10 mg/kgivermectin
LAVAGE
0
20
40
60
80
TNFα
(pg/
ml)
veh 10 mg/kgivermectin
LAVAGE
0.0
1.5
3.0
4.5
6.0
IL-1
0 (n
g/m
l)
veh 10 mg/kgivermectin
LAVAGE
0
10
20
30
40
50
IL-6
(ng/
ml)
veh 10 mg/kgivermectin
BLOOD
0
20
40
60
80
MIP
-2 (n
g/m
l)
veh 10 mg/kgivermectin
LAVAGE
0
300
600
900
1200
1500
1800
IL-1β
(pg/
ml)
veh 10 mg/kgivermectin
BLOOD
0
200
400
600
TNFα
(pg/
ml)
veh 10 mg/kgivermectin
BLOOD
0
1
2
3
4
5
6
7
veh 10 mg/kgivermectin
IL-1
0 (n
g/m
l)
BLOOD
0
15
30
45
60
IL-6
(ng/
ml)
veh 10 mg/kgivermectin
BLOOD
0
100
200
300
400
500
600
700
800
veh 10 mg/kgivermectin
IL-1β
(pg/
ml)
Supplementary Figure S7
A B C D
E F G H
I J
Supplementary Figure S8
CD45+ live cells
F4/80+
Ly6G-
F4/80-Ly6G+
SSC
-A
FSC-A CD45
Live
/Dea
d
Ly6G
F4/8
0
